Table 1.

Patient Demographics

Characteristic	No (%)
No. of patients	11 (100)
Age, years
Median (Range)	53 (36–68)
Race / ethnicity
White	6 (54.5)
Black	3 (27.3)
Asian	1 (9)
Hispanic	1 (9)
Stage of disease
Metastatic	11 (100)
Visceral only	3 (27.3)
Visceral and nonvisceral	3 (27.3)
Nonvisceral only	5 (45.4)
Hormone receptor status
ER, PR or both positive	3 (27.3)
ER and PR negative	8 (72.7)
HER2 positive (IHC combined with FISH)	11 (100)
Previous therapy
Anthracyclines	9 (81.8)
Taxanes	10 (91)
Trastuzumab as adjuvant therapy	4 (36.4)
Trastuzumab for metastatic disease	11 (100)
Cumulative duration of prior trastuzumab (wk)
Median (Range)	82 (22–136)
Time from last cycle trastuzumab to initiation of trastuzumab and pertuzumab (wk)
Median (Range)	13 (4–96)

Abbreviations: ER, estrogen receptor; PR, progestin receptor; IHC, immunohistochemistry; FISH, fluorecsence in-situ hybridization; wk, week.